Flash Note Key Financial Highlights — First Quarter 2026
Flash Note Key Financial Highlights — First Quarter 2026
EBITDA from Continuing Operations Up 11%
Paiania, May 28, 2026 — The Lavipharm Group reports an 11% increase in consolidated EBITDA from continuing operations for the first quarter of 2026, which amounted to EUR 3.13 million, compared to EUR 2.82 million in the corresponding period of the prior year. Total EBITDA from both continuing and discontinued operations declined by 16.9%, reflecting the one-off gain recognized in Q1 2025 from the divestiture of the pharmacy network, amounting to EUR 973 thousand. It should be noted that Q1 2026, as well as Q1 2025, was burdened by a non-cash (accounting) charge reflecting the fair-value measurement of stock award and stock option programs attributable to the respective period, amounting to EUR 215 thousand for the current period and EUR 239 thousand for 2025.